SG11201401343YA - TREATMENT OF DISEASE OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY - Google Patents
TREATMENT OF DISEASE OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITYInfo
- Publication number
- SG11201401343YA SG11201401343YA SG11201401343YA SG11201401343YA SG11201401343YA SG 11201401343Y A SG11201401343Y A SG 11201401343YA SG 11201401343Y A SG11201401343Y A SG 11201401343YA SG 11201401343Y A SG11201401343Y A SG 11201401343YA SG 11201401343Y A SG11201401343Y A SG 11201401343YA
- Authority
- SG
- Singapore
- Prior art keywords
- disease
- treatment
- transcriptional activity
- disorders caused
- induced nfkb
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161534081P | 2011-09-13 | 2011-09-13 | |
| PCT/US2012/055064 WO2013040153A1 (en) | 2011-09-13 | 2012-09-13 | TREATMENT OF DISEASE OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201401343YA true SG11201401343YA (en) | 2014-08-28 |
Family
ID=47883716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201401343YA SG11201401343YA (en) | 2011-09-13 | 2012-09-13 | TREATMENT OF DISEASE OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20140309224A1 (en) |
| EP (1) | EP2797598A4 (en) |
| EA (1) | EA027531B1 (en) |
| GE (1) | GEP201706771B (en) |
| SG (1) | SG11201401343YA (en) |
| UA (1) | UA112197C2 (en) |
| WO (1) | WO2013040153A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2914266B1 (en) | 2012-11-01 | 2019-06-19 | University of South Carolina | Cdk8/cdk19 selective inhibitors for use in a method for treating prostate cancer |
| MX2018005158A (en) * | 2015-11-03 | 2019-05-16 | Lu License Ab | Compounds for treatment of hypoproliferative disorders. |
| JP7142846B2 (en) | 2017-01-30 | 2022-09-28 | 国立大学法人京都大学 | NOVEL COMPOUND AND METHOD FOR PRODUCING REGULATORY T CELLS |
| EP3684420A4 (en) * | 2017-09-18 | 2021-06-16 | Chan Zuckerberg Biohub, Inc. | Methods for treating triple-negative breast cancer |
| JP7285249B2 (en) | 2017-10-02 | 2023-06-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Novel [1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors |
| US11014906B2 (en) | 2018-08-21 | 2021-05-25 | University Of South Carolina | Quinoline-based compounds and methods of inhibiting CDK8/19 |
| AU2020216498A1 (en) | 2019-02-01 | 2021-09-23 | Senex Biotechnology, Inc | Bicyclic pyridine compositions and methods of using the same for cancer therapy |
| US20240180921A1 (en) * | 2021-03-25 | 2024-06-06 | University Of South Carolina | Cdk8/19 inhibitors for the treatment of cytokine storm |
| WO2023048275A1 (en) | 2021-09-27 | 2023-03-30 | 国立大学法人京都大学 | Method for producing t cell |
| WO2023095802A1 (en) | 2021-11-24 | 2023-06-01 | レグセル株式会社 | Pharmaceutical composition for treating or preventing t cell-related disorders |
| CA3239019A1 (en) | 2021-11-24 | 2023-06-01 | Regcell Co., Ltd. | Human inducibility controllable t-cell and method for preparing same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040180844A1 (en) * | 2003-03-10 | 2004-09-16 | Fesik Stephen W. | Method of killing cancer cells |
| US7368430B2 (en) * | 2003-11-06 | 2008-05-06 | Research Development Foundation | Selective inhibitors of nuclear factor-κB activation and uses thereof |
| EP1720841B1 (en) * | 2004-02-19 | 2015-11-04 | Rexahn Pharmaceuticals, Inc. | Quinazoline derivatives and therapeutic use thereof |
| US20100190807A1 (en) * | 2008-08-26 | 2010-07-29 | Senex Biotechnology, Inc. | CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein |
| PH12012500097A1 (en) * | 2009-07-21 | 2011-01-27 | Shanghai Inst Organic Chem | Potent small molecule inhibitors of autophagy, and methods of use thereof |
-
2012
- 2012-09-13 UA UAA201403813A patent/UA112197C2/en unknown
- 2012-09-13 US US14/343,947 patent/US20140309224A1/en not_active Abandoned
- 2012-09-13 GE GEAP201213442A patent/GEP201706771B/en unknown
- 2012-09-13 EA EA201490614A patent/EA027531B1/en not_active IP Right Cessation
- 2012-09-13 WO PCT/US2012/055064 patent/WO2013040153A1/en active Application Filing
- 2012-09-13 SG SG11201401343YA patent/SG11201401343YA/en unknown
- 2012-09-13 EP EP12831933.2A patent/EP2797598A4/en not_active Withdrawn
-
2019
- 2019-08-23 US US16/549,794 patent/US20200048208A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2797598A4 (en) | 2015-08-12 |
| US20200048208A1 (en) | 2020-02-13 |
| GEP201706771B (en) | 2017-11-27 |
| US20140309224A1 (en) | 2014-10-16 |
| UA112197C2 (en) | 2016-08-10 |
| EP2797598A1 (en) | 2014-11-05 |
| EA201490614A1 (en) | 2014-06-30 |
| WO2013040153A1 (en) | 2013-03-21 |
| EA027531B1 (en) | 2017-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267547A (en) | Sensing or stimulating activity of tissue | |
| SG11201401343YA (en) | TREATMENT OF DISEASE OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY | |
| HK1211844A1 (en) | Treatment of pulmonary disease | |
| HK1201438A1 (en) | Treatment of ocular disease | |
| ZA201205829B (en) | Treatment of respiratory disorders | |
| AU339607S (en) | Medical device for treatment of sleep disorders | |
| EP2723902A4 (en) | Treatment and diagnosis of epigenetic disorders and conditions | |
| EP2704723A4 (en) | Treatment of polycystic disease | |
| EP2680842A4 (en) | Methods of treating a disease or condition of the central nervous system | |
| HK1204573A1 (en) | Treatment of inflammatory skin disorders | |
| IL225896A0 (en) | Treatment of mecp2-associated disorders | |
| IL229705A0 (en) | Methods of treating or preventing neurological diseases | |
| EP2673363A4 (en) | Treatment of angiogenesis disorders | |
| EP2729155A4 (en) | Methods of treating or preventing rheumatic disease | |
| DK2694056T3 (en) | THERAPEUTIC TREATMENT | |
| GB201107467D0 (en) | Novel treatment of pain | |
| IT1403677B1 (en) | NEW ASSOCIATION FOR PAIN TREATMENT | |
| PL395469A1 (en) | Indolamines derivatives for the treatment of diseases of the central nervous system | |
| GB201118065D0 (en) | Treatment of movement disorders | |
| GB201204645D0 (en) | Treatment of disease | |
| HK1199818A1 (en) | Treatment of seborrhoea | |
| GB201113718D0 (en) | Treatment of Dupuytren's Disease | |
| GB201101770D0 (en) | Treatment of inflammatory respiratory disease | |
| EP2911662A4 (en) | Method of treatment of disease | |
| EP2531186A4 (en) | Treatment skin disorders |